Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease

Thrombosis Research

Volumn 105, Issue 4, 2002, Pages 285-290

  Seljeflot, Ingebjørg ^a   Tonstad, Serena ^a   Hjermann, Ingvar ^a   Arnesen, Harald ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Atorvastatin; Coagulation; Coronary heart disease; Fibrinolysis; Simvastatin

Indexed keywords

ATORVASTATIN; D DIMER; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROCOAGULANT; PROTHROMBIN; SIMVASTATIN; STATIN; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; HEPTANOIC ACID DERIVATIVE; LIPID; PYRROLE DERIVATIVE;

ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FIBRINOLYSIS; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; BLOOD; CORONARY ARTERY DISEASE; HEMOSTASIS; TIME;

BLOOD COAGULATION; CORONARY DISEASE; DOUBLE-BLIND METHOD; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; PYRROLES; SIMVASTATIN; TIME FACTORS;

EID: 0037082365     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(02)00034-8     Document Type: Article

References (35)

1. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Survival Study (4S)
2. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
4. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
5. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS
6. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)
7. Statins do more than just lower cholesterol
8. Atherosclerosis involves more than just lipids: Plaque dynamics
9. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study
10. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up
11. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group
12. Hypertriglyceridemia and hypercoagulability
13. Baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography
14. Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system
15. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia
16. Effects of fluvastatin on lipids and fibrinolysis in coronary artery disease
17. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids
18. Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile
19. Antiatherothrombotic properties of statins. Implication for cardiovascular event reduction
20. Low-density lipoprotein-independent effects of statins
21. The evolving role of statins in the management of atherosclerosis
22. D-dimer test after standardized coagulation. A new assay for evaluation of the unstimulated fibrinolytic system
23. Effect of atorvastatin and simvastatin in obtaining targets for lipids in secondary prevention. The Treat-to-Target study (3T)
24. Blood collection in strong acidic citrate anticoagulant used in a study of dietary influence of basal t-PA activity
25. Gerinnungsphysiologische Schnellmetode zur Bestimmung des Bifrinogens
26. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein
27. Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels
28. Stimulating effect of oxidized low density lipoproteins of plasminogen activator inhibitor-1 synthesis by endothelial cells
29. Cholesterol lowering and endothelial function
30. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells
31. Endogenous tissue-type plasminogen activator and risk of myocardial infarction
32. Atorvastatin: An effective lipid-modifying agent in familial hypercholesterolemia
33. Inhibition of tissue-factor-mediated thrombin generation by simvastatin
34. Role of platelets in tissue factor expression by monocytes in normal and hypercholesterolemic subjects. In vitro effect of cerivastatin